The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
Open accessAbstract
The immune system can both promote and suppress cancer. Chronic inflammation and proinflammatory cytokines such as interleukin (IL)-1 and IL-6 are considered to be tumour promoting. In contrast, the exact nature of protective antitumour immunity remains obscure. Here, we quantify locally secreted cytokines during primary immune responses against myeloma and B-cell lymphoma in mice. Strikingly, successful cancer immunosurveillance mediated by tumour-specific CD4+ T cells is consistently associated with elevated local levels of both proinflammatory (IL-1α, IL-1β and IL-6) and T helper 1 (Th1)-associated cytokines (interferon-γ (IFN-γ), IL-2 and IL-12). Cancer eradication is achieved by a collaboration between tumour-specific Th1 cells and tumour-infiltrating, antigen-presenting macrophages. Th1 cells induce secretion of IL-1β and IL-6 by macrophages. Th1-derived IFN-γ is shown to render macrophages directly cytotoxic to cancer cells, and to induce macrophages to secrete the angiostatic chemokines CXCL9/MIG and CXCL10/IP-10. Thus, inflammation, when driven by tumour-specific Th1 cells, may prevent rather than promote cancer. Inflammation can result in the formation of tumours, but the immune system is also involved in the elimination of cancer cells. Here, the authors show that inflammation driven by tumour-specific CD4+T cells results in tumour regression and identify a list of cytokines associated with cancer prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,094
Bonecchi, R., Bianchi, G., Bordignon, P. P., D'Ambrosio, D., Lang, R., Borsatti, A., Sozzani, S., Allavena, P., Gray, P. A., Mantovani, A., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.1.129 · Cited by 2,014
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764
Multiple Defects of Immune Cell Function in Mice with Disrupted Interferon-γ Genes
Dalton, D. K., Pitts-Meek, S., Keshav, S., Figari, I. S., Bradley, A., & Stewart, T. A. (1993) · Science · doi:10.1126/science.8456300 · Cited by 1,727
Stromal gene expression predicts clinical outcome in breast cancer
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Omeroglu, G., Meterissian, S., Omeroglu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,687
Basement membrane complexes with biological activity
Kleinman, H. K., McGarvey, M. L., Hassell, J. R., Star, V. L., Cannon, F. B., Laurie, G. W., & Martin, G. R. (1986) · Biochemistry · doi:10.1021/bi00350a005 · Cited by 1,502
Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.688 · Cited by 1,391
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
Kim, S., Takahashi, H., Lin, W.-W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J.-L., & Karin, M. (2009) · Nature · doi:10.1038/nature07623 · Cited by 1,100
IL-1 is required for tumor invasiveness and angiogenesis
Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C. A., & Apte, R. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437939100 · Cited by 1,023
Budhu, A., Forgues, M., Ye, Q.-H., Jia, H.-L., He, P., Zanetti, K. A., Kammula, U. S., Chen, Y., Qin, L.-X., Tang, Z.-Y., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.016 · Cited by 846
Tumor-specific Th17-polarized cells eradicate large established melanoma
Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 845
Philip, R., & Epstein, L. B. (1986) · Nature · doi:10.1038/323086a0 · Cited by 767
Lasagni, L., Francalanci, M., Annunziato, F., Lazzeri, E., Giannini, S., Cosmi, L., Sagrinati, C., Mazzinghi, B., Orlando, C., Maggi, E., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021897 · Cited by 739
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo.
Angiolillo, A. L., Sgadari, C., Taub, D. D., Liao, F., Farber, J. M., Maheshwari, S., Kleinman, H. K., Reaman, G. H., & Tosato, G. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.1.155 · Cited by 705
Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation
Ben-Sasson, S. Z., Hu-Li, J., Quiel, J., Cauchetaux, S., Ratner, M., Shapira, I., Dinarello, C. A., & Paul, W. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902745106 · Cited by 568
CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help
Nakanishi, Y., Lu, B., Gerard, C., & Iwasaki, A. (2009) · Nature · doi:10.1038/nature08511 · Cited by 548
Qin, Z., & Blankenstein, T. (2000) · Immunity · doi:10.1016/s1074-7613(00)80218-6 · Cited by 511
Primary Antitumor Immune Response Mediated by CD4+ T Cells
Corthay, A., Skovseth, D. K., Lundin, K. U., Røsjø, E., Omholt, H., Hofgaard, P. O., Haraldsen, G., & Bogen, B. (2005) · Immunity · doi:10.1016/j.immuni.2005.02.003 · Cited by 478
Self-citationThe beige mutation in the mouse selectively impairs natural killer cell function
Roder, J., & Duwe, A. K. (1979) · Nature · doi:10.1038/278451a0 · Cited by 460
Luster, A. D., Greenberg, S. M., & Leder, P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.1.219 · Cited by 446
Inflammation and prognosis in colorectal cancer
Klintrup, K., Mäkinen, J. M., Kauppila, S., Väre, P. O., Melkko, J., Tuominen, H., Tuppurainen, K., Mäkelä, J., Karttunen, T. J., & Mäkinen, M. J. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.07.017 · Cited by 431
Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Morris, S. B., Burdick, M. D., Glass, M. C., Taub, D. T., Iannettoni, M. D., Whyte, R. I., & Strieter, R. M. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.981 · Cited by 353
Twelve immunotherapy drugs that could cure cancers
‘Mac’ Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 341
Unitt, E., Marshall, A., Gelson, W., Rushbrook, S. M., Davies, S., Vowler, S. L., Morris, L. S., Coleman, N., & Alexander, G. J. M. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.12.027 · Cited by 257
MHC class II—Restricted presentation of intracellular antigen
Weiss, S., & Bogen, B. (1991) · Cell · doi:10.1016/0092-8674(91)90506-t · Cited by 257
Self-citationMig, the Monokine Induced By Interferon-γ, Promotes Tumor Necrosis In Vivo
Sgadari, C., Farber, J. M., Angiolillo, A. L., Liao, F., Teruya-Feldstein, J., Burd, P. R., Yao, L., Gupta, G., Kanegane, C., & Tosato, G. (1997) · Blood · doi:10.1182/blood.v89.8.2635 · Cited by 246
Schreiber, R. D., Pace, J. L., Russell, S. W., Altman, A., & Katz, D. H. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.131.2.826 · Cited by 235
Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-Free Survival in Breast Cancer
Kohrt, H. E., Nouri, N., Nowels, K., Johnson, D., Holmes, S., & Lee, P. P. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020284 · Cited by 220
Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo
Sgadari, C., Angiolillo, A. L., Cherney, B. W., Pike, S. E., Farber, J. M., Koniaris, L. G., Vanguri, P., Burd, P. R., Sheikh, N., Gupta, G., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13791 · Cited by 217
Martı́n, F., Santolaria, F., Batista, N., Milena, A., González-Reimers, E., Brito, M. J., & Oramas, J. (1999) · Cytokine · doi:10.1006/cyto.1998.0398 · Cited by 207
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.
Levitsky, H. I., Lazenby, A., Hayashi, R. J., & Pardoll, D. M. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.4.1215 · Cited by 189
Bogen, B., Malissen, B., & Haas, W. (1986) · European Journal of Immunology · doi:10.1002/eji.1830161110 · Cited by 175
Self-citationMeta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma
Rohatiner, A. Z. S., Gregory, W. M., Peterson, B., Borden, E., Solal-Celigny, P., Hagenbeek, A., Fisher, R. I., Unterhalt, M., Arranz, R., Chisesi, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.146 · Cited by 170
von Stebut, E., Ehrchen, J. M., Belkaid, Y., Kostka, S. L., Mölle, K., Knop, J., Sunderkötter, C., & Udey, M. C. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030159 · Cited by 158
Vidal‐Vanaclocha, F., Amezaga, C. A. V.-D., Asumendi, A., Kaplanski, G., & Dinarello, C. A. (1994) · PubMed · Cited by 146
Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors.
Lauritzsen, G. F., Weiss, S., Dembić, Z., & Bogen, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5700 · Cited by 139
Self-citationPelliniemi, T., Irjala, K. M. A., Mattila, K. J., Pulkki, K. J., Rajamäki, A., Tienhaara, A., Laakso, M., & Lahtinen, R. (1995) · Blood · doi:10.1182/blood.v85.3.765.bloodjournal853765 · Cited by 133
CD4 regulatory T cells in human cancer pathogenesis
Knutson, K. L., Disis, M. L., & Salazar, L. G. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0194-y · Cited by 122
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma
Preti, H. A., Cabanillas, F., Talpaz, M., Tucker, S. L., Seymour, J. F., & Kurzrock, R. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-3-199708010-00002 · Cited by 112
Different patterns of inflammation and prognosis in invasive carcinoma of the breast
Lee, A. H. S., Gillett, C., Ryder, K., Fentiman, I. S., Miles, D. W., & Millis, R. R. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02410.x · Cited by 88
Naive CD4+ T cells confer idiotype‐specific tumor resistance in the absence of antibodies
Bogen, B., Munthe, L. A., Sollien, A., Hofgaard, P. O., Omholt, H., Dagnaes, F., Dembić, Z., & Lauritzsen, G. F. (1995) · European Journal of Immunology · doi:10.1002/eji.1830251114 · Cited by 81
Self-citationWetzler, M., Kurzrock, R., Estrov, Z. E., Kantarjian, H. M., Gisslinger, H., Underbrink, M., & Talpaz, M. (1994) · Blood · doi:10.1182/blood.v84.9.3142.3142 · Cited by 70
Konishi, N., Miki, C., Yoshida, T., Tanaka, K., Toiyama, Y., & Kusunoki, M. (2005) · Oncology · doi:10.1159/000086768 · Cited by 60
Corthay, A., Lundin, K. U., Lorvik, K. B., Hofgaard, P. O., & Bogen, B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4816 · Cited by 57
Self-citationCai, T., Nesi, G., Boddi, V., Mazzoli, S., Canto, M. D., & Bartoletti, R. (2006) · Oncology Reports · doi:10.3892/or.16.2.329 · Cited by 27
Cited by
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Gu-Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., Ravoet, M., Le Buanec, H., Sibille, C., Manfouo-Foutsop, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67428 · Cited by 1,070
The clinical role of the TME in solid cancer
Giraldo, N. A., Sanchez-Salas, R., Peske, J. D., Vano, Y., Becht, E., Petitprez, F., Validire, P., Ingels, A., Cathelineau, X., Fridman, W. H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0327-z · Cited by 732
A Longitudinal Big Data Approach for Precision Health
Schüssler-Fiorenza Rose, S. M., Contrepois, K., Moneghetti, K. J., Zhou, W., Mishra, T., Mataraso, S., Dagan-Rosenfeld, O., Ganz, A. B., Dunn, J., Hornburg, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0414-6 · Cited by 494
Interleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
Metadata
- Authors
- Haabeth, O. A. W., Lorvik, K. B., Hammarström, C., Donaldson, I. M., Haraldsen, G., Bogen, B., & Corthay, A.
- Venue
- Nature Communications
- Published
- 2011-03-15
- Volume
- 2
- Issue
- 1
- Pages
- 240-240
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2048455086
- Cited by
- 318
- References
- 56
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.